Korean biopharma that developed and markets Xcopri (cenobamate), an epilepsy drug, directly in the US through its own subsidiary.
Korean biopharma that developed and markets Xcopri (cenobamate), an epilepsy drug, directly in the US through its own subsidiary.
Earns product sales of Xcopri directly in the US, and licence fees and royalties from partners that sell it elsewhere: in Europe Angelini Pharma markets it as Ontozry. Its own US sales team means it keeps the full revenue from its main market. Controlled by SK Inc., the Korean conglomerate's holding company.
Moat: narrow (IP / patents, regulatory licence). Patented epilepsy drug with FDA approval and its own US sales force, unusual for a Korean biopharma.
Headquarters: Seongnam, South Korea · Founded: 2011 · Employees: 272
Size SKBP (326030.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $5.03B, the 81st largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩85,900 on 18 Nov 2026.
Performance Over six months the shares fell 16.1%, against +10.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 37.4% over the last twelve months (peer median +11.3%); the operating margin is 37.6% (peer median 20.6%).
Valuation It trades at 21.5× forward earnings against a peer median of 28.7× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +94%, so the hurdle is -98 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 36.0 points above its cost of capital (5.6% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩928B | ₩707B | ₩548B | ₩355B | ₩246B |
| Revenue growth | — | +29% | +54% | +44% | — |
| Gross profit | ₩863B | ₩652B | ₩492B | ₩308B | ₩197B |
| EBITDA | ₩365B | ₩221B | ₩114B | -₩22.8B | -₩118B |
| Net income | ₩381B | ₩267B | ₩241B | -₩32.9B | -₩139B |
| Free cash flow | ₩273B | ₩174B | ₩91.5B | -₩98.2B | -₩165B |
| Capital expenditure | ₩32.5B | ₩29.5B | ₩13.4B | ₩3.25B | ₩5.96B |
| Total debt | ₩43.6B | ₩48.9B | ₩184B | ₩178B | ₩156B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SKBP 326030.KS | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% |
| Jazz Pharmaceuticals Public JAZZ | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% |
| Eisai 4523.T | $9.36B | +11% | +11% | 6% | 26.6× | 10.7% |
| Supernus Pharmaceuticals SUPN | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% |
| Xenon Pharmaceuticals XENE | $3.71B | -31% | -100% | n/a | n/a | n/a |
| Praxis Precision Medicines PRAX | $8.53B | -9% | -100% | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 326030.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.3% | -1.2% | 4th highest of 21 |
| 6-month return | -16.1% | +10.6% | 3rd lowest of 21 |
| Distance from 52-week high | -40.4% | -21.1% | 5th lowest of 21 |
| Revenue growth (TTM) | +37.4% | +11.3% | 4th highest of 19 |
| Operating margin | 37.6% | 20.6% | 4th highest of 19 |
| Forward P/E | 21.5× | 28.7× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -4.4% | 7.3% | 3rd least demanding of 17 |
| Growth delivered (Del g) | +93.6% | +12.5% | 3rd highest of 17 |
| Hurdle (Req g minus delivered) | -98.0 pp | -2.6 pp | 3rd least demanding of 17 |
| ROIC minus cost of capital | +36.0 pp | +4.6 pp | 5th highest of 17 |
| EV / EBITDA | 17.2× | 22.8× | 4th cheapest of 11 |
| Net debt / EBITDA | -1.2× | -0.7× | 5th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% | +4.0% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |